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Abstract
Background and objectives: Visceral leishmaniasis (VL) is an important public health problem in south-eastern Nepal
affecting very poor rural communities. Since 2005, Nepal is involved in a regional initiative to eliminate VL. This study
assessed the economic impact of VL on households and examined whether the intensified VL control efforts induced by the
government resulted in a decrease in household costs.
Methods: Between August and September 2010, a household survey was conducted among 168 patients that had been
treated for VL within 12 months prior to the survey in five districts in south-eastern Nepal. We collected data on health-
seeking behaviour, direct and indirect costs and coping strategies.
Results: The median total cost of one episode of VL was US$ 165 or 11% of annual household income. The median delay
between the onset of symptoms and presentation to a qualified provider was 25 days. Once the patient presented to a
qualified provider, the delay to correct diagnosis was minimal (median 3 days). Direct and indirect costs (income losses)
represented 47% and 53% of total costs respectively. Households used multiple strategies to cope with the cost of illness,
mainly mobilizing cash/savings (71%) or taking a loan (56%).
Conclusions: The provision of free VL diagnosis and drugs by the Nepalese control programme has been an important
policy measure to reduce the cost of VL to households. But despite the free VL drugs, the economic burden is still important
for households. More effort should be put into reducing indirect costs, in particular the length of treatment, and preventing
the transmission of VL through vector control.
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Introduction
Since 2005, the Government of Nepal has been involved in a
Visceral Leishmaniasis (VL) elimination programme, alongside the
governments of India and Bangladesh, to reduce annual VL
incidence to less than one case per 10,000 population by 2015 [1].
VL, also known as kala-azar, is a parasitic disease that is fatal if
treatment is not provided timely. The disease is transmitted from
humans-to-humans through the bite of a female sandfly.
Geographically, VL occurs in the alluvial plains of the river
Ganges, in districts bordering the frontiers between Bangladesh,
India and Nepal. The cases in this region account for 60% of the
global burden of VL. In Nepal, 8 million people are at risk of
acquiring VL in 12 districts in the central and eastern regions of
the country [2]. Between 2000 and 2010, 17,462 cases and 244
deaths were reported in Nepal although these figures, obtained
through passive case surveillance at government health facilities,
are likely to be underestimations since many cases are not reported
or remain undetected [3–5].
The cornerstones of the VL elimination initiative are early
detection and appropriate treatment, in an attempt to curtail
transmission of the disease. A standardized clinical case definition
was adopted, the rK39 rapid diagnostic test was introduced to
enable faster detection of suspected cases and miltefosine, the first
oral drug for VL, replaced sodium stibogluconate (SSG) to which
growing failure rates had been reported in Nepal [6]. In addition,
both VL diagnosis and drugs are now provided free of charge at
public health care facilities. These measures along with enhanced
vector control resulted in a steady decrease in the annual number
of reported VL cases in Nepal from 2,229 in 2003 to 900 in 2010.
Another important outcome of the improved case management
strategy may be its effect on the household costs of seeking and
obtaining appropriate VL care. VL is a disease of poverty affecting
the poorest of the poor [7,8]. Households with low incomes and
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living in precarious housing conditions such as mud -or grass
covered houses are most at risk of acquiring VL disease [9, Uranw
et al. unpublished data]. The few studies in Nepal quantifying the
economic burden of VL on households and conducted prior to the
elimination initiative showed a VL episode to profoundly impact
the socio-economic status of the household. Adhikari et al. (2009)
reported that up to 26% of previously non-poor households were
pushed into poverty as a direct result of out-of-pocket expenditures
on VL care while Rijal et al. 2006 showed that the (median) direct
and indirect costs of a VL episode were equal to one year of
median per capita income. Usually an expenditure exceeding 10%
of annual household income is defined as catastrophic, meaning it
drives households into destitution [10,11]. These high costs are
caused, amongst others, by long delays, up to 2 months, before
correct diagnosis whereby households consulted traditional and
private-for-profit providers [12] as well as the long hospitalization
due to the use of SSG. Faster screening of suspected cases,
enhanced access to free treatment, and a different treatment
regimen may reduce these household costs. We examined whether
the intensified VL control efforts induced by the elimination
initiative resulted in a demonstrable impact at household level in
terms of health seeking behaviour, costs and coping strategies.
Methods
Nepal is administratively divided into 14 zones and 75 districts.
In 2010, VL was reported in 12 districts situated in south-eastern
Nepal in the Terai region bordering the highly VL-endemic
northern state of Bihar in India. The study was conducted between
August and September 2010 in five of these highly endemic
districts, namely Siraha, Saptari, Sunsari, Morang and Jhapa. VL
incidence rates in the study districts varied from 0.52 cases per
10,000 persons per year (Sunsari district) to 2.03 cases per 10,000
persons per year (Saptari district) in 2010 (table 1).
We searched the medical records of the District Public Health
Office in each district and the database of the B.P. Koirala
Institute of Health Sciences (BPKIHS) to identify all households in
the five districts with a household member treated for kala-azar
within 12 months prior to the survey. BPKIHS is a tertiary level
hospital situated in Sunsari district and draws many patients from
the surrounding areas due to its widespread reputation as a VL
treatment and research centre. Patients treated at BPKIHS are not
included in the medical records of the District Public Health
Office. Furthermore, to minimize recall bias, we only considered
the most recent case of VL in the household.
Organization of VL care services
Health care services at the district level are provided by sub-
health posts, health posts, primary health care centres and district
hospitals (i.e. primary care level) [13]. A network of female
community health volunteers at the village level refer patients to
health -and sub-health posts. Patients suspected of VL (defined as
individuals with a history of fever of more than 2 weeks with a
palpable spleen) seeking care from female community health
volunteers, sub-health posts and health posts are referred to
primary health care centres or district hospitals for diagnosis by a
rapid diagnostic test (rK39 immunochromatographic strip test). If
positive, the patient is treated at the PHC or referred to a district
hospital (or higher level) if the PHC does not have a medical
doctor, which is often observed. All VL drugs are provided free of
costs. Diagnosis through parasitology (bone marrow or splenic
aspiration) can only be done at district hospitals or above. While
private formal providers such as private clinics also provide
diagnosis and treatment of VL, free treatment is only available at
public facilities. Various anti-leishmanial drugs are available in
Nepal: since 2006 SSG, administrated intramuscularly for 30 days,
was replaced as first line treatment by miltefosine, an oral drug
given for 28 days. Due to its possible teratogenic effect, miltefosine
Author Summary
Visceral leishmaniasis (VL) is a parasitic disease and is fatal
if untreated. VL mainly affects poor populations in rural
areas and has important socio-economic consequences to
the household because of high expenditures to access
treatment and coping strategies to cover the costs of care.
Since 2005, the government of Nepal has been engaged in
a regional collaborative effort to eliminate VL from the
Indian subcontinent. In this study we examined the
economic burden of VL from the perspective of the
household after the intensified implementation of VL
control activities. Our findings indicate that the economic
burden of VL as a percent of household income has
decreased compared to studies conducted prior to the
implementation of the VL elimination initiative in Nepal. In
particular, the free provision of diagnosis and drugs at
public health facilities has been an important policy
measure. However, the economic impact of VL is still
considerable and efforts are needed to further reduce the
burden of VL to affected households or prevent the
transmission of VL.
Table 1. Characteristics of districts included in the study.
Siraha Saptari Sunsari Morang Jhapa
Location Central Terai East Terai East Terai East Terai East Terai
Population, 2006 638,375 633,965 710,842 941,614 755,494
VL cases, 2006* 142 255 117 113 52
Case detection rate# 22.2 40.2 16.5 12 6.9
Cases in survey (% of
notified cases in 2006)
8 (5.6) 54 (21.2) 12 (10.3) 78 (69.0) 16 (30.8)
Source: National Population & Housing Census 2011; adapted from [23].
*Notified to Epidemiology and Diseases Control Division, Nepal.
#Number of new cases reported per 100 000 person-years.
doi:10.1371/journal.pntd.0002062.t001
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is not given to pregnant women. The second line treatment is
amphotericin B deoxycholate given every day for 14 doses.
Data collection and analysis
Information for the study was obtained from patient medical
records and a household questionnaire. Medical records at the
District Public Health Offices and the BPKIHS were consulted to
retrieve data on the type of VL drugs received and the length of
treatment. Subsequently households were visited at their home-
stead by a team of trained field workers who had previously been
involved in other kala-azar related community and household
surveys in the area. The field workers were supervised on a daily
basis by the first author (S. Uranw). They used a pre-tested
structured questionnaire administered to the head of the
household or the most knowledgeable person. The survey collected
data on treatment seeking behaviour (health providers visited,
mode of travel, delay to presentation to first qualified health
professional, etc.), direct and indirect costs and the coping
strategies to meet the health seeking and treatment costs.
Direct medical and non-medical cost data were gathered for
each provider visited. Direct medical costs included all out-of-
pocket expenditures by the household on consultation, medicines
and laboratory tests. Direct non-medical costs included expendi-
ture on transportation to and from the health facility, food costs
and other daily expenditures for the patient and accompanying
family members. The indirect cost of a VL episode represented the
loss of productivity within the household due to illness and was
estimated using the human capital approach. The loss of
productivity was valued in terms of the loss of earnings of the
patient and household members caring for the patient (either at
home or hospital). For patients and attendants, the daily wage rate
was estimated and multiplied by the number of work days lost to
obtain the indirect cost of a VL episode. The daily wage rate was
determined by asking a series of questions on the daily monetary
income (the main source of income to most household members
was daily labour). For patients and attendants reporting farming as
their main source of income, the survey collected data on the
yearly production of each produce which was then valued with
local market prices and divided by the number of agriculturally
active household members. We also estimated total household
income as the sum of monthly cash income from daily labour for
each economically active household member, the income from
agriculture, income from sales of animals and animal products
(e.g. milk) and remittances from family members.
Analysis
The data is described using descriptive statistics showing
proportions, means and standard deviations. We also presented
medians and interquartile ranges (25th and 75th percentile) because
of skewed distributions in the cost data; many households reported
zero out-of-pocket expenditure for some cost categories and
providers, in particular informal health care providers. Costs were
defined as catastrophic if they exceeded 10% of annual household
income [10,11]. All costs were converted from Nepalese rupees
(Rs.) to US dollars using the exchange rate prevailing at the time of
the study (1 USD=Rs. 74.8; OANDA August 2010). Data entry
and cleaning were done in Microsoft Excel and analysis in STATA
v10.1 (Stata Corp., College Station Tx, USA).
Ethical considerations
Ethical clearance was obtained from the ethics committee of the
BP. Koirala Institute of Health Sciences, Nepal and the ethics
committee of the University of Antwerp, Belgium. Patient’s
medical records were reviewed retrospectively and all information
retrieved from medical records was anonymized. Signed informed
consent was obtained from all adult patients and from a parent or
guardian of participating minors. All households that were
approached for the study, whether they accepted to participate
or not, received a free long-lasting insecticide treated net
(Vestergaard Frandsen A/S, Denmark) as a compensation for
their time spent with the survey team.
Results
Characteristics of study participants and the household
We randomly retrieved a total of 200 households where a case
of VL occurred in the past 12 months in the five districts, of which
168 households were located by field workers and accepted to be
interviewed. The majority of patients were male (60%) and 41 of
them were head of the household (24%). Most patients were over
14 years of age (68%); the median age was 19 (IQR 12.5-35). Male
patients were significantly older than female (median age 22.5
versus 17.0; p,0.05). The percentage of women of childbearing
age (15–49 years) among patients was 19%. The median
household size was 5.7 persons.
Out of 168 patients, sixty-one (36%) were economically active at
the time of illness, most of them day labourers (80%) such as
rickshaw driver or farm labourers. Few patients were engaged in
small-scale farming (n= 5; 8%) or were salaried workers (n = 4;
6%). The median monthly income of an economically active
patient (n = 60) was Rs. 6,000 or 81 US$ (range 27–162 US$). The
median monthly income of the household (n = 168) was Rs. 10,243
or 138 US$ (range 87–163 US$) giving a median per capita
monthly income of Rs. 1,882 or 25 US$ (range 20–30 US$).
The vast majority of households lived in non-permanent
housing structures either consisting entirely of natural materials
(49%) or a combination, usually mud walls and metal sheets as
roof (45%). Eighteen per cent of households owned land (n= 30);
27 of these households cultivated some crops on their land, mainly
paddy rice and wheat. Most households also owned some livestock
(83%), usually goats (56% of households; median 3 heads), cows
(44%, median 2.5) or chickens (36%, median 5). Fifty-eight per
cent of households owned a bicycle, 56% a mobile phone and 36%
a radio.
Health-seeking behaviour
Patients visited a median of 2 health providers including the one
who eventually treated them (IQR 1–2) (table 2). For 91
households (55%), a public provider was the patient’s first point
of contact; other households first visited a private (qualified)
provider (n = 34; 20%), a traditional healer (n = 26; 15%) or a
chemist or pharmacy (n= 16; 10%). The main reasons behind the
choice of the first provider were proximity (49%) and the
perceived (good) reputation of the health provider (38%).
Traditional healers were chosen for their proximity, public
providers (health centre or hospital) most often for their reputation
while for private providers it was a mix of both. Ninety patients
(54%) were submitted to a VL diagnostic test on their first visit but
this varied considerably by type of provider: all patients presenting
at public hospitals were tested for VL, compared to 56% at public
health centres and 39% at private providers. Of the patients that
did not receive a VL diagnostic test at a public health centre or a
private provider on their first visit, respectively 60% and 55% were
subsequently referred by the provider to a public hospital for
testing and treatment. Households that used the services of an
unqualified provider first, were more likely to visit either another
unqualified provider or a private provider afterwards. Approxi-
mately 21% (n= 35) of households visited three different providers;
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4% (n= 7) of households visited 4 different types of health
providers.
The median delay between the onset of symptoms and
presentation to a qualified health provider (i.e. patient delay)
was 25 days (IQR 20–30). Once the patient had presented to a
qualified provider, the median delay to correct diagnosis of VL
was 3 days (IQR 2–7). The total median delay from onset of
symptoms to start of treatment was 31 days (IQR 23–35). While
none of the delays varied with age or gender, there was a
significant and positive relationship between the total delay and
the number of providers visited (p,0. 01).
Treatment regimens
The vast majority of patients in our study were treated with
either miltefosine (83%) or conventional amphotericin B (15%) in
case of relapse as recommended by the 2005 guidelines of the VL
elimination initiative [1]. Four patients were treated with SSG
(2%), two of them by a public provider. The other two patients
treated with SSG by a private provider were unexpected in our
survey because these patients are usually not included in the
DPHO records. In addition, both patients reported not to have
paid for the SSG drugs. Upon closer inspection, these patients
were from the same village in Morang district on the border with
Bihar state (India). After discussion with the local vector control
officer, they had probably obtained the SSG free of charge from a
private charitable hospital in Bihar and subsequently received the
injections at a health facility in Nepal by trained health workers.
Direct costs
The average and median direct household costs incurred by
type of provider are given in table 3. All but three patients received
VL treatment at a public hospital, the remaining 3 patients were
treated at a public health centre (n = 1) or a private qualified
provider (n = 2).
The median direct cost of an episode of VL across all providers
was Rs. 4,905 (IQR 3,025–7,125) or US$ 66 (IQR 41–96). Direct
medical costs were Rs. 2,390 (IQR 1,100–4,290) and non-medical
costs Rs. 2,300 (IQR 1,550–3,350) or 51% and 49% respectively
of total median direct costs. Direct medical costs arose from
expenditures on consultation fees, miscellaneous drugs and
laboratory investigations (including diagnostic tests). The survey
confirmed that none of the households had to pay for VL drugs.
Median direct medical costs were highest for households visiting
private providers (median Rs. 2000; IQR 1,475–3,575), in
particular payments for ancillary drugs (e.g. antibiotics, antipyret-
ics or vitamin injections). The direct non-medical costs, consisting
of transportation, food and other expenses (i.e. small daily
expenses) were highest at the public hospital. The high food costs
at public hospitals (median: Rs. 1,400; IQR 700–2,000) arose from
the hospitalization of the patient and accompanying family
member(s) for VL treatment. The median duration of hospitalisa-
tion was 10 days (IQR 7–16) and was the same for patients
receiving SSG or miltefosine but higher for patients treated with
conventional amphotericin B (median: 14 days; IQR 8–20). Direct
(medical and non-medical) costs did not vary by gender or income
quintiles, but direct medical costs increased with the patient’s age.
Indirect costs
VL is a syndrome characterized by prolonged fever, weight loss,
anaemia, fatigue and enlargement of the liver and spleen. As a
result patients are either severely limited or not able at all to carry
out their daily activities and need much support from family
members. Among the 168 patients, 95% (n= 160) reported that
VL illness had a severe impact on their normal functioning and
resulted in a loss of income to the household, either wage losses to
the patient or caretakers, losses in agricultural output or other
earnings. Patients reported not being able to carry out their
normal daily activities for a median number of 57 days (IQR 51–
65) (table 4). As a result the median loss of income was Rs. 12,400
for economically active patients. Since only 36% of patients were
economically active, the value of time lost across all patients, both
the economically active and non-active, was on average Rs. 4,731.
Patients were attended by on average 1.1 household members
(range: 1–2). These caretakers reported a median loss of 15
workdays (IQR 10–30) mainly due to accompanying the patient to
the various health providers and staying with him/her for the full
duration of hospitalization. The median loss of income to
caretakers was Rs. 2,583 (on average Rs. 2,279 across all
caretakers). The median total value of time lost to the household
per episode of VL was Rs. 4,500 (IQR 1,500–12,167).
Table 2. Health seeking behaviour of households (n = 168).
Variable N6 (%) of patients
Type of health provider first visited
Traditional 26 (15.5)
Chemist or pharmacy 16 (9.5)
Village health worker 6 (3.6)
Public, primary 23 (13.7)
Public, hospital 63 (37.5)
Private doctor/clinic 34 (20.2)
Delay to presentation (in days) (median; IQR) 25 (20–30)
Delay to diagnosis (in days) (median; IQR) 3 (2–7)
Number of health providers visited
1 63 (37.5)
2 70 (41.6)
3 28 (16.7)
4 7 (4.2)
Diagnosed with VL at first visit?
Yes 90 (53.6)
No 78 (46.4)
Mode of transportation to first facility
Foot 38 (22.6)
Bicycle 28 (16.7)
Bus 96 (57.1)
Other 6 (3.6)
Mode of transportation to treatment facility1
Foot 4 (2.4)
Bicycle 10 (6.0)
Motorbike 2 (1.2)
Bus 148 (88.6)
Other 3 (1.8)
Distance between home and treatment
facility (kilometers)
,20 45 (26.8)
20–60 86 (51.2)
.60 37 (22.0)
1The treatment facility is the health provider where the patient received VL
treatment. In 98% of cases this was a public hospital.
doi:10.1371/journal.pntd.0002062.t002
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Coping strategies
Households used a number of strategies to cope with the costs of
VL illness. Many of these strategies resulted in additional costs to
the household; e.g. in terms of interest payments on loans or hiring
labour to replace the sick household member. The survey
identified three strategies to cope with the financial costs of VL
illness: mobilizing cash/savings, taking a loan and sales of
livestock. Mobilizing cash or savings was the most frequent coping
strategy. Seventy-one per cent (n = 120) of households used their
savings to pay for health care expenditures, although for 54% of
these households it was not enough to cover all medical costs. Out
of those 120 households, 75% (n= 90) of households reported that
the savings were supposed to buy food, in other cases assets
(n = 30). Fifty-six per cent (n = 94) of households took a loan to
finance the costs of care, most often from a member of the same
village (71%), followed by friends or peers (17%) or an informal
money lender (6%). When borrowing from friends, the loan was
interest free. In other cases (n = 57), the amount to be repaid was
on average 140% the original amount borrowed, usually through
monthly instalments. A collateral was not often provided for the
loan: four households provided assets as collateral, one household
that took a loan from a bank provided their house. Seventeen per
cent of households sold livestock to cover the costs of care (n = 29).
Forty-two per cent of households chose more than one strategy
Table 3. Direct medical and non-medical costs of treatment per patient by type of provider (Rs. 2010).
Traditional (n= 28) Chemist/pharmacy (n=25) Village health worker (n =6)
Mean (sd) Median
(IQR
25–75) Mean (sd) Median
(IQR
25–75) Mean (sd) Median
(IQR
25–75)
Direct medical costs
Consultation 210 (363) 50 (0–200) 74 (76) 50 (10–100) 72 (114) 30 (10–60)
Ancillary drugs 425 (847) 0 (0–750) 1,242 (1,526) 700 (500–1,400) 657 (242) 670 (500–800)
Laboratory
investigations
45 (137) 0 (0–0) 225 (218) 100 (0–400) 67 (103) 0 (0–200)
Total direct
medical costs
679 (973) 300 (0–1,000) 2,034 (2,950) 1,150 (500–2,000) 795 (325) 785 (650–1,000)
Direct non–medical
costs
Transportation 7 (30) 0 (0–0) 113 (194) 0 (0–100) 0 (0) 0 (0–0)
Food 314 (567) 0 (0–350) 107 (149) 0 (0–200) 17 (26) 0 (0–50)
Other 0 (0) 0 (0–0) 2 (10) 0 (0–0) 8 (20) 0 (0–0)
Total direct
non-medical costs
321 (564) 0 (0–350) 222 (319) 100 (0–200) 25 (42) 0 (0–50)
Total direct costs 1,001 (1,150) 775 (75–
1,700)
2,256 (3,158) 1,150 (500–2,200) 820 (350) 785 (700–1,000)
Public, primary (n=32) Public, hospital (n =165) Private doctor/clinic (n =52) Total costs all providers
Mean (sd) Median
(IQR
25–75) Mean (sd) Median
(IQR
25–75) Mean (sd) Median
(IQR
25–75) Mean (sd) Median
(IQR
25–75)
Direct medical costs
Consultation 56 (85) 25 (10–50) 79 (191) 50 (25–70) 222 (155) 200 (200–
250)
203 (297) 88 (40–
270)
Ancillary drugs 1,002 (845) 600 (500–
1,345)
1,120 (1,580) 650 (400–
1,080)
1,714 (1,567) 1,200 (825–
2,000)
2,134 (2,137) 1,500 (700–
2,850)
Laboratory
investigations
317 (349) 200 (95–425) 442 (603) 300 (200–
500)
748 (767) 500 (300–
875)
786 (872) 600 (300–
1,000)
Total direct
medical costs
1,375 (1,107) 975 (608–
1,900)
1,550 (1,703) 1,000 (720–
1,688)
2,684 (2,038) 2,000 (1,475–
3,575)
3,123 (2,745) 2,390 (1,100–
4,290)
Direct non–medical
costs
Transportation 75 (114) 23 (0–100) 431 (343) 450 (200–
500)
390 (392) 300 (150–
500)
574 (481) 500 (300–
800)
Food 123 (144) 100 (0–200) 1,424 (968) 1,400 (700–
2,000)
414 (571) 200 (100–
500)
1,619 (1,018) 1,500 (1,000–
2,250)
Other 29 (97) 0 (0–0) 239 (216) 200 (100–
400)
68 (183) 0 (0–0) 260 (252) 200 (100–
480)
Total direct non-
medical costs
226 (290) 125 (23–275) 2,090 (1,207) 2,000 (1,300–
2,700)
882 (1,007) 600 (300–
1,100)
2,453 (1,400) 2,300 (1,550–
3,350)
Total direct costs 1,601 (1,266) 1,075 (693–
2,260)
3,640 (2,531) 3,130 (2,135–
4,223)
3,582 (2,545) 2,500 (2,000–
5,000)
5,576 (3,552) 4,905 (3,025–
7,125)
doi:10.1371/journal.pntd.0002062.t003
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(n = 71), mainly using cash/savings and a loan (n= 47), while 2%
(n= 4) had to revert to all three strategies to cope with the costs of
VL illness.
Households also used various strategies to compensate the
labour lost due to VL illness. Nine households hired external
labour to replace either the patient or caretakers in the field at a
rate of Rs. 200 per day for a median of 60 days (IQR 60–60).
Twenty-three per cent of patients were replaced by a family
member that was a school-going child for the duration of their
illness (n = 14).
Discussion
During the past five years, considerable efforts were made by
public health authorities in Nepal towards the elimination of VL
such as the decentralisation and provision of free diagnosis and
treatment and the introduction of the oral drug miltefosine in the
public health system. In this study we studied the health seeking
behaviour and documented household costs and coping strategies
for one episode of VL from the perspective of the patient in a
miltefosine-based treatment program. From our findings, the
following observations can be made.
First, our results showed that the cost of a VL episode to patients
and their family was high notwithstanding the free provision of
drugs and diagnostics by the government. With a median total cost
of US$ 165 per episode, the economic burden of VL across all
households was 11% of annual household income or 57% of
median annual per capita income (table 5). This cost included both
direct costs (medical and non-medical out-of-pocket expenditures)
and indirect costs (productive time losses due to illness). While
about half (51%) of the households exceeded the catastrophic
threshold of 10% of annual household income, it would be wrong
to conclude that the economic consequences of VL illness were not
significant for the other households. Because VL is a disease of
poverty primarily affecting the poorest income groups [8], the
ability to cope with the costs of VL illness are limited. This was
evident from the coping strategies households used whereby a
majority of households were forced to take a loan to pay for the
costs of care and/or use all their savings. However, without the
free provision of VL drugs the median cost of an episode of VL
would be US$ 226 and the proportion of households exceeding the
catastrophic threshold would increase from 51% to 74% (assuming
a drug cost of US$63 for a 28-days course of miltefosine at WHO
preferential prices [14]).
Secondly, direct costs accounted for 47% of total costs and were
largely caused by out-of-pocket expenditures households made on
ancillary drugs and food. Households that visited private-for-profit
health providers incurred substantial expenditures on ancillary
drugs. These ancillary drugs, most frequently antibiotics, antipy-
retics or vitamin injections, were given to patients prior to their
referral to a public hospital for VL treatment. From our study we
cannot say whether the prescription of these ancillary drugs were
justified on medical grounds. Besides the ancillary drugs, another
important direct cost component were the high food costs for the
patient and accompanying relatives and was caused by the
extensive stay at the hospital for treatment. Although miltefosine is
an oral drug, patients stayed at the hospital for a median of 10
days.
A number of studies had been carried out prior to the VL
elimination initiative [12,15,16]. Our findings seem to suggest
Table 4. Indirect costs (Rs. 2010).
Mean (sd) Median (IQR 25–75)
Patients’ duration of illness (days)1 60 (18) 57 (51–65)
Number of attendants per patient 1.1 (0.3) 1.0 (1.0–1.0)
Workdays lost by attendants 21 (16) 15 (10–30)
Loss of income; working patients only (n = 61) 13,030 (5,638) 12,400 (9,800–15,400)
Loss of income; all patients (n = 168) 4,731 (7,136) 0 (0–10,700)
Loss of income working attendants only (n = 134) 3,112 (2,300) 2,583 (1,500–4,000)
Loss of income; all attendants (n = 183) 2,279 (2,404) 1,500 (0–3,100)
Total loss of income to the household£ 7,213 (7,217) 4,500 (1,500–12,167)
Total payment on loan* 2,611 (2,176) 2,080 (1000–3,300)
Total indirect cost 8,084 (7,391) 5,167 (3,000–13,290)
1Consists of the various types of delays plus the treatment duration.
£Across all patients & attendants.
*For those with interest payments.
doi:10.1371/journal.pntd.0002062.t004
Table 5. Summary of direct and indirect costs per VL episode
(Rs. and in US$ 2010).
Mean Median
Item Rs. US$ Rs. US$
Direct and indirect costs:
- Direct medical cost 3,116 42.2 2,385 32.3
- Direct non-medical costs 2,444 33.1 2,297 31.1
- Indirect cost 8,084 110.7 5,167 70.8
Total household costs 13,659 187.1 12,050 165.1
Annual income:
- Household 127,074 1,720.7 122,665 1,661.0
- Per capita 23,366 316.4 22,539 305.2
Median costs as a % of:
- Annual household income 11%
- Annual per capita income 57%
Exchange rate 1 US$ = 74 Rs. (Sept. 2010).
doi:10.1371/journal.pntd.0002062.t005
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that, compared to these studies, the economic burden of VL (as a
% of household income) has decreased. In particular the
magnitude of indirect costs (as a % of total costs) was less in our
study likely due to a shorter patient delay. We cannot say whether
the shorter patient delay observed in this study was the result of
increased patient knowledge of VL, but the previous studies
reported that traditional providers were most commonly the
patient’s first choice of provider, which may have lengthened the
delay until VL diagnosis. However, these conclusions need to be
considered as tentative. For instance the total cost of VL in our
study was higher compared to Rijal et al. (2006) but much lower
compared to Adhikari & Maskay (2005) and Adhikari et al. (2009)
while the household income of VL affected households in our
study was higher compared to all three studies (to enable
comparisons the cost data in these articles were adjusted to the
year 2010 using the consumer price index [17]). While daily wages
in Nepal have increased over the years, partly to compensate for
the high inflation rate, methodological differences between the
studies and in particular the small sample sizes of the first two
studies (respectively 18 and 7 households) limit their generaliz-
ability beyond the communities or villages where these studies
were carried out.
Despite the provision of free VL drugs, we have shown that
households still incurred substantial medical out-of-pocket expen-
ditures, especially at private providers. It remains to be seen,
however, if these medical costs can be prevented or at least
diminished. While prepayment schemes, such as community-based
health insurance, may be a solution, coverage in Nepal is very low
and expansion of coverage to VL affected households is unlikely in
the near future. More realistic and feasible approaches consist of
reducing indirect costs and vector control. Treatment duration can
be reduced substantially by considering alternative VL drugs to
miltefosine as single-dose liposomal amphotericin B or a short
course combination therapy [18]). Vector control, such as indoor
residual spraying, has been shown to be effective in reducing the
number of sandflies inside the house [19,20] and may therefore
reduce disease transmission. Since 2011, the Government of Nepal
has also introduced a conditional cash transfer programme
whereby households receive Rs. 1,000 (US$13.5) upon completion
of treatment at a public hospital [21]. This payment can be used to
cover transportation costs but was not yet in place when we carried
out the household survey. However from our study, the total
transportation costs of households were smaller than Rs. 1,000
while food costs were higher. The conditional cash programme
therefore ought to be expanded to include food costs as well.
This study had a number of limitations. Because patients were
selected from the medical records of the District Public Health
Offices and the BPKIHS, only patients treated at public health
facilities were included in the study. The records kept by the
District Public Health Offices are obtained through passive
surveillance from cases detected and treated by public health
facilities. Private for-profit providers are not required to report
patients treated at their facilities. Due to the low incidence of VL
and the high number of private practioners in Nepal, it would
have been difficult and costly to find and interview these patients.
Because patients exclusively treated at private-for-profit providers
were excluded, we probably underestimated the true burden of
VL. Despite this limitation, our findings were still representative
for a large proportion of the VL population because in Nepal,
contrary to India, a relatively small proportion of patients seek VL
treatment from private-for-profit providers (about 11% of patients
according to [22]. Nonetheless, efforts should be made in the
future to include the private sector in the control of VL.
A second limitation is related to the recall bias. With decreasing
VL incidence rates in Nepal, we have chosen a recall of 12 months
to allow the identification of a sufficient number of households. To
minimize the recall bias we only analysed the most recent case of
VL in the household. Because of the clustering of VL in
communities and villages, several cases of VL often occur in the
same household. For instance, in 44% of households in our study
one or more members had been treated for VL before, often
within a few years. The occurrence of more than one case of VL in
the same household would significantly increase the economic
impact of VL to households. And even if these cases do not occur
in the same year, the risk of impoverishment and indebtedness
would still be much higher.
Conclusion
With a shorter delay to diagnosis once the patient has presented
to a qualified health provider and the free provision of the correct
first-line drug, our study indicates that the case management
component of the Nepalese VL programme performs rather well.
In particular free VL diagnosis and drugs at public health facilities
have been an important policy measure in Nepal to lower financial
barriers and improve access to VL diagnosis and care. Without
this policy the economic burden of VL would have been much
higher. However, the economic impact of VL is still considerable
and intensified efforts are needed to further reduce the burden of
VL to affected households or prevent the transmission of VL.
These include shortening the duration of stay at the hospital and
expanding demand side financing mechanisms to cover a wider
range of costs incurred by households.
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